Analystreport

Biohaven (NYSE:BHVN) had its price target lowered by analysts at JPMorgan Chase & Co. from $47.00 to $15.00. They now have an "overweight" rating on the stock.

Biohaven Pharmaceutical Holding Company Ltd. Common Shares  (BHVN) 
Last biohaven pharmaceutical holding company ltd. common shares earnings: 2/25 04:45 pm Check Earnings Report
US:NYSE Investor Relations: investors.biohavenpharma.com